Liposomal daunorubicin (DaunoXome) in children with recurrent or progressive brain tumors

Pediatric Hematology and Oncology

Volumn 16, Issue 2, 1999, Pages 131-139

  Lippens, R J J ^a,b  

^a Ctr Pediat Oncol S E N   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Brain tumor; Children; Daunorubicin; Liposome

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; ETOPOSIDE; VINCRISTINE;

ADOLESCENT; ARTICLE; BONE MARROW DEPRESSION; BRAIN TUMOR; CANCER SURVIVAL; CARDIOTOXICITY; CHILD; CLINICAL ARTICLE; DEPRESSION; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HAIR LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; MALE;

EID: 0032966349     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.1080/088800199277452     Document Type: Article

References (25)

1. Levin VA. A pharmacologic basis for brain tumor chemotherapy. Semin Oncol. 1975;2:57-61.
2. Mooney C, Thomas DGT, Souhami RL. Adriamycin in the treatment of relapsed primary malignant brain tumors. Eur J Cancer Clin Oncol. 1983;19:1037-1038.
3. Benjamin RS, Weernik PH, Bachur NR. Adriamycin chemotherapy: efficacy, safety and pharmacologic basis of an intermittent, single high-dose schedule. Cancer. 1974;33:19-27.
4. Bigotte L, Olson Y. Cytofluoresce localization of adriamycin in the nervous system, III: distribution in the brain of normal adult mice after intraventricular and arachnoidal injection. Acta Neuropathol (Berl). 1982;58:193-202.
5. Niewelt EA, Pagel M, Barrett P, Glassberg M, Frenkel EP. Pharmacology and toxicity of intracarotid adriamycin administration following osmotic blood-brain barrier modification. Cancer Res. 1981;41: 4466-4470.
6. Todorov DK, Ninjo SS, Zeller WJ. Antiproliferative activity of liposomal epirubicin on experimental human glioma in vitro and in vivo after intratumoral/interstitial application. J Cancer Res Clin Oncol. 1995;121:164-168.
7. Gill PS, Espina BM, Muggia F, et al. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol. 1995;13:996-1003.
8. Gennuso R, Spiegelman MK, Chinot M, et al. Effect of blood-brain barrier and blood-tumor barrier modification on central nervous system liposomal uptake. Cancer Invest. 1993;11:118-128.
9. Gabizon AA. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 1992;52:891-896.
10. Siegal T, Horowitz A, Gabizon A. Doxorubicin encapsulated in spherically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J Neurosurg. 1995;83:1029-1037.
11. Vantongelen K, coordinator editor. A Practical Guide to EORTC Studies. Brussels: EORTC; 1994.
12. Sobotka-Plojhar MA. Anthracycline Cardiotoxicity in Children: An Echocardiographic Study. Amsterdam, The Netherlands: VU University Press: 1991:20. Thesis.
13. Pound P, Bonoron-Adele AS, Gouverneur G, Tariosse L, Besse P, Robert J. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention. Br J Pharmacol. 1996;117:1593-1599.
14. Janknegt R. Liposomal formulations of cytotoxic drugs. Support Care Cancer. 1996;4:298-304.
15. Forssen EA, Coulter DM, Proffitt RT. Selective in vivo localization of daunomycin small unilamellar vesicles in solid tumors. Cancer Res. 1992;52:3255-3261.
16. Forssen EA, Male-Brune R, Adler-Moore JP, Lee MJ, Schmidt PG, Keasieva TB, Shimizu S, Tromberg BJ. Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue. Cancer Res. 1996;56:2066-2075.
17. Forssen EA, Ross IR: DaunoXome treatment of solid tumours: preclinical and clinical investigation. Liposome Res. 1994;4:481-512.
18. Vestar IC: DaunoXome (Liposomal Daunorubicin). Physician's brochure for named patient use in Europe for Kaposi's sarcoma. San Dimas, CA; 1993.
19. Rosa P, Clementi F. Liposomes containing doxorubicin: an example of drug targetting. In: Antoline R, ed. Transport in Biomembranes: Model Systems and Reconstruction. New York: Raven; 1982:243.
20. Tokes ZA, StPeteri AK, Todd JA. Availability of liposome content to the nervous system: liposomes and the blood-brain barrier. Brain Res. 1980;188:282-286.
21. Guaglianone P, Chan K, DelaFlor-Weiss E, et al. Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome). Invest New Drugs. 1994;12:103-110.
22. Gabizon AA. Liposomal anthracyclines. Hematol Oncol Clin North Am. 1994;8;431-450.
23. Bayley CC, chairman. UKCCSG/SIOP P.N.E.T. Study III (UKCCSG 9102). Leicester, UK; 1992.
24. Pendergrass TW, Milstein JM, Geyer JR, et al. Eight drugs in one day chemotherapy for brain tumors: experience in 107 children and rationale for preradiation chemotherapy. J Clin Oncol. 1987;5:1221-1231.
25. Göbel U, Calaminus G, Teske C, et al. BEP/VIP bei Kinder und Jugendlichen mit malignen nichttesti-kulären Keimzelltumoren. Klin Pädiat. 1993;205:231.